12 Month Price Forecast For LVTX
Distance to LVTX Price Forecasts
LVTX Price Momentum
🤔 Considering Lava Therapeutics (LVTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 4:06 AM UTC
LVTX Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, LVTX has a consensus that is neutral. The median price target is $1.99, with forecasts ranging from $1.97 to $2.95. Currently, there are 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With LVTX currently trading at $0.96, the median price forecast suggests a 108.1% upside. The most optimistic forecast comes from at , projecting a 209.1% upside, while at provides the most conservative target, suggesting a 106.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LVTX Analyst Consensus
LVTX Price Target Range
Latest LVTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LVTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $2.00 |
| Dec 12, 2024 | Leerink Partners | Daina Graybosch | Market Perform | Downgrade | $2.00 |
| Dec 11, 2024 | JMP Securities | Reni Benjamin | Market Perform | Downgrade | $6.00 |
| Aug 21, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $6.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $6.00 |
| Mar 21, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $6.00 |
| Nov 17, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $6.00 |
| Aug 23, 2023 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $6.00 |
| Aug 23, 2023 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $6.00 |
| Jun 15, 2023 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $6.00 |
| Jun 12, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $9.00 |
| Jun 9, 2023 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $6.00 |
| Apr 13, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $9.00 |
| Feb 17, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $9.00 |
| Oct 25, 2022 | HC Wainwright & Co. | Arthur He | Buy | Initiates | $9.00 |
| Sep 27, 2022 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $28.00 |
| Sep 15, 2022 | JMP Securities | Reni Benjamin | Market Outperform | Initiates | $6.00 |
| May 18, 2022 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $25.00 |
| Dec 22, 2021 | SVB Leerink | Outperform | Maintains | $0.00 | |
| Nov 16, 2021 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $20.00 |
Stocks Similar to Lava Therapeutics B.V.
The following stocks are similar to Lava Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lava Therapeutics B.V. (LVTX) Financial Data
Lava Therapeutics B.V. has a market capitalization of $25.13M with a P/E ratio of -0.6x. The company generates $7.40M in trailing twelve-month revenue with a 48.6% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -371.5% and return on equity of -45.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Lava Therapeutics B.V. (LVTX) Company Overview
About Lava Therapeutics B.V.
Develops immuno-oncology therapies for cancer treatment.
LAVA Therapeutics N.V. operates as a clinical-stage biopharmaceutical company that focuses on developing innovative cancer therapies using its proprietary Gammabody platform. The company generates revenue through research collaborations, licensing agreements, and potential product commercialization as it advances its bispecific antibody candidates through clinical trials.
The company's lead candidate, LAVA-1207, is currently in Phase 1/2a trials for metastatic castration-resistant prostate cancer, and it has additional drug candidates targeting solid tumors and hematologic malignancies. Collaborations with major pharmaceutical companies like Janssen Biotech and Merck & Co. enhance its development capabilities and market potential. Founded in 2016, LAVA Therapeutics is based in Utrecht, the Netherlands.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
37
CEO
Mr. Stephen Allen Hurly M.B.A., M.Sc.
Country
Netherlands
IPO Year
2015
Website
www.lavatherapeutics.comLava Therapeutics B.V. (LVTX) Latest News & Analysis
LAVA Therapeutics has dosed the first patient in a Phase 1 study for LAVA-1266, a bispecific gamma delta T cell engager targeting CD123 for hematologic cancers.
LAVA Therapeutics' first patient dosing in a Phase 1 trial for LAVA-1266 signals progress in cancer treatment, potentially enhancing its market value and attracting investor interest.
LAVA Therapeutics (NASDAQ: LVTX) reported Q3 2024 financial results and announced a strategic reprioritization of its pipeline focused on bispecific gamma delta T cell engagers.
LAVA Therapeutics' financial results and pipeline changes can signal shifts in growth potential and risk, impacting stock valuations and investor sentiment in the immuno-oncology sector.
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
5 months agoLAVA Therapeutics CEO Stephen Hurly will present at the H.C. Wainwright 26th Annual Global Investment Conference, highlighting the company's bispecific gamma delta T cell engagers.
LAVA Therapeutics' CEO presentation at a major investment conference signals potential for increased visibility and investor interest, possibly impacting stock performance and market perception.
LAVA Therapeutics (NASDAQ: LVTX) reported Q2 2024 financial results and shared updates on its Gammabody® platform for bispecific gamma delta T cell engagers.
LAVA Therapeutics' financial results and updates on its Gammabody® platform could impact future funding, partnerships, and stock performance, key factors for investors evaluating growth potential.
4 Stocks Under $5 To Buy Now
5 months agoInvestors may consider stocks with low price tags for potential buying opportunities.
Low-priced stocks may indicate undervalued opportunities, attracting investors seeking potential growth. They can also reflect higher risk, impacting investment strategies and portfolio diversification.
LAVA Therapeutics (LVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.
LAVA Therapeutics' upgrade to a Zacks Rank #1 signals strong earnings potential, likely attracting more investors and driving stock price upward.
Frequently Asked Questions About LVTX Stock
What is Lava Therapeutics B.V.'s (LVTX) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Lava Therapeutics B.V. (LVTX) has a median price target of $1.99. The highest price target is $2.95 and the lowest is $1.97.
Is LVTX stock a good investment in 2025?
According to current analyst ratings, LVTX has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LVTX stock?
Wall Street analysts predict LVTX stock could reach $1.99 in the next 12 months. This represents a 108.1% increase from the current price of $0.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lava Therapeutics B.V.'s business model?
LAVA Therapeutics N.V. operates as a clinical-stage biopharmaceutical company that focuses on developing innovative cancer therapies using its proprietary Gammabody platform. The company generates revenue through research collaborations, licensing agreements, and potential product commercialization as it advances its bispecific antibody candidates through clinical trials.
What is the highest forecasted price for LVTX Lava Therapeutics B.V.?
The highest price target for LVTX is $2.95 from at , which represents a 209.1% increase from the current price of $0.96.
What is the lowest forecasted price for LVTX Lava Therapeutics B.V.?
The lowest price target for LVTX is $1.97 from at , which represents a 106.0% increase from the current price of $0.96.
What is the overall LVTX consensus from analysts for Lava Therapeutics B.V.?
The overall analyst consensus for LVTX is neutral. Out of 5 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $1.99.
How accurate are LVTX stock price projections?
Stock price projections, including those for Lava Therapeutics B.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
